We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors.
- Authors
Ghiringhelli, François; Apetoh, Lionel; Tesniere, Antoine; Aymeric, Laetitia; Ma, Yuting; Ortiz, Carla; Vermaelen, Karim; Panaretakis, Theocharis; Mignot, Grégoire; Ullrich, Evelyn; Perfettini, Jean-Luc; Schlemmer, Frédéric; Tasdemir, Ezgi; Uhl, Martin; Génin, Pierre; Civas, Ahmet; Ryffel, Bernhard; Kanellopoulos, Jean; Tschopp, Jürg; André, Fabrice
- Abstract
The therapeutic efficacy of anticancer chemotherapies may depend on dendritic cells (DCs), which present antigens from dying cancer cells to prime tumor-specific interferon-γ (IFN-γ)–producing T lymphocytes. Here we show that dying tumor cells release ATP, which then acts on P2X7 purinergic receptors from DCs and triggers the NOD-like receptor family, pyrin domain containing-3 protein (NLRP3)-dependent caspase-1 activation complex ('inflammasome'), allowing for the secretion of interleukin-1β (IL-1β). The priming of IFN-γ–producing CD8+ T cells by dying tumor cells fails in the absence of a functional IL-1 receptor 1 and in Nlpr3-deficient (Nlrp3−/−) or caspase-1–deficient (Casp-1−/−) mice unless exogenous IL-1β is provided. Accordingly, anticancer chemotherapy turned out to be inefficient against tumors established in purinergic receptor P2rx7−/− or Nlrp3−/− or Casp1−/− hosts. Anthracycline-treated individuals with breast cancer carrying a loss-of-function allele of P2RX7 developed metastatic disease more rapidly than individuals bearing the normal allele. These results indicate that the NLRP3 inflammasome links the innate and adaptive immune responses against dying tumor cells.
- Subjects
DENDRITIC cells; ANTINEOPLASTIC agents; CANCER chemotherapy; TUMOR antigens; ANTHRACYCLINES; IMMUNE response; T cells
- Publication
Nature Medicine, 2009, Vol 15, Issue 10, p1170
- ISSN
1078-8956
- Publication type
Article
- DOI
10.1038/nm.2028